Nplate (romiplostim) for Injection, for Subcutaneous Use
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
April 2016
ADVERSE REACTIONS
Clinical Trials Experience
Bone Marrow Reticulin Formation and Collagen Fibrosis
Nplate...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Clinical Trials | Drugs & Pharmacology